Do platelet function analyzer-100 testing results correlate with bleeding events after percutaneous renal biopsy?
Measuring PFA-100 is unlikely to add to the care of patients undergoing routine PKB. ClinicalTrials.gov NCT00334204.
Altogether, these data suggest a novel function for apigenin, acting as a suppressor of AKT/PKB pathway in PEL cells, and raise the possibility that this agent may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of the AKT/PKB pathway.